NCT02765204View on ClinicalTrials.gov

A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin

DRUG

Saxagliptin

DRUG

Glucose

Trial Locations (1)

75185

Dept of Medical Sciences Uppsala University Hospital, Uppsala

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Uppsala University

OTHER